MW150 for Alzheimer's Disease
(SKI-AD Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial requires that your neuropsychiatric medications be stable for at least 2 months before starting. It doesn't specify about other medications, so you should discuss your current medications with the study team.
Is MW150 safe for humans?
How does the drug MW150 differ from other Alzheimer's treatments?
What is the purpose of this trial?
This trial is testing a new pill called MW150 for people with mild-to-moderate Alzheimer's disease. The pill works by blocking a brain protein that may cause Alzheimer's symptoms. The study aims to see if the pill is safe and if it helps improve memory and daily activities.
Research Team
Lawrence S Honig, MD PhD
Principal Investigator
Columbia University
Eligibility Criteria
This trial is for men and women aged 50-90 with mild-to-moderate Alzheimer's Disease, who have a study partner and can speak English fluently. Participants must not have significant other medical conditions or psychiatric disorders, no recent drug/alcohol abuse, and if female, be non-childbearing. Males must agree to use contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 10 mg MW150 or placebo daily for 84 days to assess safety, tolerability, and effects on cognitive performance and biomarkers
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- MW150
Find a Clinic Near You
Who Is Running the Clinical Trial?
Neurokine Therapeutics
Lead Sponsor
National Institute on Aging (NIA)
Collaborator
Columbia University
Collaborator